Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Interleukin-6 blocking agents for treating COVID-19: a living systematic review
Lina Ghosn, Rouba Assi, Theodoros Evrenoglou, et al.
Cochrane library (2023) Vol. 2023, Iss. 6
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Targeting the host response in sepsis: current approaches and future evidence
Christian Bode, Sebastian Weis, Andrea Sauer, et al.
Critical Care (2023) Vol. 27, Iss. 1
Open Access | Times Cited: 24
Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma
Quigly Dragotakes, Patrick W. Johnson, Matthew R. Buras, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 41
Open Access | Times Cited: 5
Respiratory disorders
Alice Carter, Mervyn Singer, Andrew Webb
Oxford University Press eBooks (2025), pp. 365-406
Closed Access
mTORC1 syndrome (TorS): unifying paradigm for PASC, ME/CFS and PAIS
Jacob Bar‐Tana
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID‐19; a systematic review and meta‐analysis of randomized clinical trials
Driton Vela, Zana Vela‐Gaxha, Mjellma Rexhepi, et al.
British Journal of Clinical Pharmacology (2021) Vol. 88, Iss. 5, pp. 1955-1963
Open Access | Times Cited: 28
Influence of extracorporeal cytokine adsorption on hemodynamics in severe acute pancreatitis: Results of the matched cohort pancreatitis cytosorbents inflammatory cytokine removal (PACIFIC) study
Sebastian Rasch, Sengül Sancak, Johanna Erber, et al.
Artificial Organs (2022) Vol. 46, Iss. 6, pp. 1019-1026
Open Access | Times Cited: 21
Current treatment challenges in the COVID-19 pandemic
Filippo Patrucco, Francesco Gavelli, Sharmila Fagoonee, et al.
Polskie Archiwum Medycyny Wewnętrznej (2021) Vol. 131, Iss. 9, pp. 854-861
Open Access | Times Cited: 26
Sustained IL‐6 and sTNF‐αR1 levels after hip fracture predict 5‐year mortality: A prospective cohort study from the Baltimore Hip Studies
Saionara Maria Aires da Câmara, Marc C. Hochberg, Ram R. Miller, et al.
Journal of the American Geriatrics Society (2024) Vol. 72, Iss. 9, pp. 2644-2655
Closed Access | Times Cited: 2
Mesenchymal Stem Cells in the Treatment of COVID-19
Bei-Cyuan Guo, Kang‐Hsi Wu, Chun‐Yu Chen, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14800-14800
Open Access | Times Cited: 7
Patients with Castleman disease report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination
Saishravan Shyamsundar, Sheila K. Pierson, Caoilfhionn M Connolly, et al.
Deleted Journal (2024) Vol. 1, Iss. 1, pp. 100002-100002
Open Access | Times Cited: 1
Kinetics of pro- and anti-inflammatory spike-specific cellular immune responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: a prospective longitudinal study in Japan
Tomoyuki Kakugawa, Yusuke Mimura, Yuka Mimura‐Kimura, et al.
Immunity & Ageing (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 1
Retrospective Observational Analysis of Tocilizumab Outcomes in COVID-19 Patients at a Tertiary Care Hospital
Vrushali Aringale, Bharti Daswani, Madeline Fernandes
Journal of Pharmaceutical Care (2024)
Open Access | Times Cited: 1
Cyclosporin a as an Add-On Therapy to a High Dose Corticosteroid-Based Background Treatment in Patients With COVID-19: A Multicenter Randomized Clinical Trial
Lucía Llanos, Beatriz Álvarez-Álvarez, Eva Fonseca Aizpuru, et al.
(2024)
Open Access | Times Cited: 1
Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms
Yijun Wu, Xu Sun, Kai Kang, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 1
Polypharmacy and the In Silico Prediction of Potential Body Proteins Targeted by These Drugs Among Hospitalized COVID-19 Patients With Cytokine Storm
Ghazwan A. M. Raouf, F. K. Mohammad, Muayad Aghali Merza
Cureus (2023)
Open Access | Times Cited: 4
COVID-19: An Update on Epidemiology, Prevention and Treatment, September-2023
Serap Şimşek Yavuz
Infectious Diseases and Clinical Microbiology (2023) Vol. 5, Iss. 3, pp. 165-187
Open Access | Times Cited: 2
Tocilizumab in hospitalized patients with severe COVID-19 pneumonia: A single-center observational study
Hüseyin Kaya
Eurasian Journal of Pulmonology (2024), pp. 41-50
Open Access
Efficacy of interleukin-6 inhibitors as a tool for preventive anti-inflammatory therapy for COVID-19
S. К. Zyryanov, О. И. Бутранова, A. A. Abramova
Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice (2024), Iss. 1, pp. 4-16
Open Access
Kinetics of pro- and anti-inflammatory spike-specific T-cell responses in long-term care facility residents after COVID-19 mRNA primary and booster vaccination: A prospective longitudinal study in Japan
Tomoyuki Kakugawa, Yusuke Mimura, Yuka Mimura‐Kimura, et al.
Research Square (Research Square) (2024)
Open Access
Pharmacological validation of a novel exopolysaccharide from Streptomyces sp. 139 to effectively inhibit cytokine storms
Zhuochen Zhuang, Yu Chen, Zhe Liu, et al.
Heliyon (2024) Vol. 10, Iss. 14, pp. e34392-e34392
Open Access
Factors Affecting Mortality in COVID-19 Patients Treated with Tocilizumab
Osman Cüre, Kadir İlkkılıç, Bayram Şen, et al.
Eastern Journal Of Medicine (2024) Vol. 29, Iss. 3, pp. 359-366
Open Access
Cyclosporin A as an Add-On Therapy to a Corticosteroid-Based Background Treatment in Patients with COVID-19: A Multicenter, Randomized Clinical Trial
Lucía Llanos, Beatriz Álvarez-Álvarez, Eva Fonseca Aizpuru, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 17, pp. 5242-5242
Open Access
An exploratory analysis of associations of genetic variation with the efficacy of tocilizumab in severe COVID-19 patients. A pharmacogenetic study based on next-generation sequencing
Alejandro Durán‐Sotuela, Jorge Vázquez-García, S. Relaño-Fernández, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Development of a prediction nomogram for IgG levels among asymptomatic or mild patients with COVID-19
Jianying Yi, Zhili Liu, Xi Cao, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access
IS TOCILIZUMAB AN EFFECTIVE THERAPY FOR SEVERE COVID-19: A SINGLE CENTER STUDY
Samreen Sarfaraz, Quratulain Shaikh, Sundus Iftikhar, et al.
Journal of Ayub Medical College Abbottabad (2022) Vol. 34, Iss. 4, pp. 751-758
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top